Request Trial
shutterstock_1537866854_sundry_photography
Sundry Photography / Shutterstock.com
2 November 2021AmericasMuireann Bolger

Nevro faces $20m damages in patent dispute with Boston Scientific

Medical device company Nevro has been hit with a $20m damages verdict after a US jury found that it had infringed two patents owned by Boston Scientific.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Sanofi suffers setback in insulin monopoly dispute
29 January 2026   A judge has allowed antitrust claims against the pharma giant to move forward, finding that it plausibly used bundled rebates and patent abuse to extend its insulin monopoly, though one allegation was dismissed.
Americas
Eli Lilly’s Mounjaro tops list of cyber squatter targets
28 January 2026   The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026   As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper


Editor's picks

The quantum advantage: IP considerations for the next generation of life sciences innovation
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

Editor's picks

Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026

More features

Winston & Strawn and Taylor Wessing UK seal ‘powerhouse’ merger
Pearce IP grows practice with senior patent hire
Sanofi suffers setback in insulin monopoly dispute
Firm adds seven-lawyer team in second major merger
Eli Lilly’s Mounjaro tops list of cyber squatter targets
The quantum advantage: IP considerations for the next generation of life sciences innovation
Fed Circ overturns PTAB decision in $83.4m DNA case
Simpson Thacher adds ‘exemplary’ litigator with emerging tech expertise